VolitionRx appoints Dr. Andrew Retter as Chief Medical Officer effective April 1, 2024

VOLITIONRX LTD

Dr. Retter is an Intensive Care Consultant at Guy's and St. Thomas' NHS Foundation Trust, London, and dual-registered in Intensive Care and Haematology.
He has advised Volition since January 2022 on Nu.Q® NETs, a CE-marked blood test for sepsis and NETosis-related diseases.
As CMO, he will lead medical strategy and ensure clinical efforts are aligned with patient needs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.